May 30,2007
Sen. Grassley seeks additional information about pricing and marketing of anti-anemia drugs
WASHINGTON --- Sen. Chuck Grassley is asking a leading drug maker to cooperate with his ongoing inquiry into the pricing and marketing of anti-anemia drugs given to kidney and cancer patients and the Food and Drug Administration’s access to data from the drug maker’s studies of such drugs.
The text of the letter Grassley sent today to Johnson & Johnson is below, along with the text of inquiries he made earlier this month and in April of the Food and Drug Administration, Amgen Inc. and the Centers for Medicare and Medicaid Services.
Grassley is Ranking Member of the Senate Committee on Finance.
###
Next Article Previous Article
Recent News
- As Trump Sits on Key Epstein Files, Wyden Lays Out “Follow the Money” Investigation for DOJ
- Across the Country, Health Insurance Premiums Set to Spike Thanks to Trumpcare
- Wyden Statement on HHS and Treasury Department Nominees at Finance Committee Hearing
- Ahead of committee vote, Wyden opposes Treasury and USTR nominees
- Bipartisan Delegation Urges De-Escalation of US-Canada Trade Conflict In Meeting with Canadian Prime Minister Carney